Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat.
about
A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic painAn analysis of enzyme kinetics data for mitochondrial DNA strand termination by nucleoside reverse transcription inhibitorsAging of the human innate immune system in HIV infection.HIV research in Australia: linking basic research findings with clinical and public health outcomes.Epidemiology and management of antiretroviral-associated cardiovascular disease.Peripheral neuropathy in HIV: prevalence and risk factorsHIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue.Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic DamageChanges in Inflammation, Oxidative Stress, Mitochondrial DNA Content after Rosiglitazone in HIV Lipoatrophy.Mitochondrial DNA content, an inaccurate biomarker of mitochondrial alteration in human immunodeficiency virus-related lipodystrophy.Fatigue-related gene networks identified in CD(14)+ cells isolated from HIV-infected patients: part I: research findings.Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments.Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection.Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy statusThe Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain.Elevated serum fibroblast growth factor 21 levels correlate with immune recovery but not mitochondrial dysfunction in HIV infection.In vivo mitochondrial function in HIV-infected persons treated with contemporary anti-retroviral therapy: a magnetic resonance spectroscopy study.Apoptosis: a clinically useful measure of antiretroviral drug toxicity?A review of the toxicity of HIV medications.Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity.Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND.A case of possible darunavir/ritonavir-induced peripheral neuropathy: case description and review of the literature.Adipose Tissue in HIV Infection.Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition.Blepharoptosis and external ophthalmoplegia associated with long-term antiretroviral therapy.[HIV-associated neuropathies].Quantitative analysis of human mitochondrial DNA using a real-time PCR assay.Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals.IL-1beta (+3954C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome.Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).
P2860
Q28469254-5A8D30FD-619F-4B59-9CD1-02BCC2DA82DDQ28474361-4B5D1395-FC44-4529-82A0-659AA74AE302Q34094201-9D0B9727-DD32-42A7-84BB-48DD5BEF9A5FQ35215246-1DF5A7C4-141D-4981-BF6B-5EFB7E42286EQ35338096-359BFD83-1545-4D87-8810-E8332CFD7641Q35384460-42BAB14B-44D6-4B4F-B261-A147254572CAQ35975980-3BDD3B29-3273-45BE-979D-9AB5AB6CA005Q36313228-1A40ABAB-C25E-4B6D-B100-0171C0C4733EQ36439056-630DDBF4-5022-4593-9D96-FE0D243E29FEQ36447515-091F3333-4FC8-4644-8E24-6975C72455FBQ36593775-97F16225-98A2-4809-8CF6-06F21BA7A3D1Q36683940-010F9579-6ADF-4C9E-8B74-447ED04DDBE2Q36880847-45032773-6DE1-48C6-BBB9-5DA9E128AE29Q37038329-35AE32A5-83FE-44BB-9EF1-AA854F557DB6Q37114196-E1968930-71A8-4D5C-9888-533D5AB3B214Q37149019-7564CE70-1F53-4ABF-A980-689FD3843DD7Q37418033-34A3717A-9D63-42E9-8DB2-DC55D30296EBQ37444962-3EBC08E9-3A38-49B1-B66C-565A8E6BC7E1Q37604387-A5441F08-9382-4811-8174-B3226CF74464Q37633495-BA4AD113-4C7E-48AD-B8FE-97A40AFE2845Q37634512-2E3194C4-3CB7-4931-A071-D8CF61E214A2Q37721505-A52B1A9B-DF1A-462C-801F-736DF1C1CE42Q38087942-578EB93A-561A-44AC-9297-45A12A6C3A7DQ40038736-4CE1AC12-2E77-44D7-A030-378AE89F297BQ40241691-FA4B9B83-4E5E-4EE4-BCEF-9C078EF47846Q43508252-CCD5F4DF-2938-4CFC-BA66-470198443443Q44083431-CD07F596-C06E-4C02-9B1C-0C21B8DB1055Q44511932-2687491A-1C62-4F95-B64D-17712BBBE1DEQ44612861-CFAA7264-C66E-4466-A98B-4F50CDBA414AQ45051217-15C515DC-693D-4239-A9A2-9B19A881A48DQ45396453-42784473-8FCB-4F98-9D6A-76B4006EB41BQ51460886-08024B5A-B0C0-4988-8D12-5FB42C11A538
P2860
Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Exposure to dideoxynucleosides ...... drial DNA in subcutaneous fat.
@en
Exposure to dideoxynucleosides ...... drial DNA in subcutaneous fat.
@nl
type
label
Exposure to dideoxynucleosides ...... drial DNA in subcutaneous fat.
@en
Exposure to dideoxynucleosides ...... drial DNA in subcutaneous fat.
@nl
prefLabel
Exposure to dideoxynucleosides ...... drial DNA in subcutaneous fat.
@en
Exposure to dideoxynucleosides ...... drial DNA in subcutaneous fat.
@nl
P2093
P1476
Exposure to dideoxynucleosides ...... drial DNA in subcutaneous fat.
@en
P2093
Catherine L Cherry
Jennifer F Hoy
Justin C McArthur
Michelle E Gahan
Steven L Wesselingh
P304
P356
10.1097/00126334-200207010-00002
P407
P577
2002-07-01T00:00:00Z